Table 3.
Effect on serum biomarkers and lipid profile against alloxan-induced diabetic complications.
| Treatment | AST (IU/L) | ALT (IU/L) | ALP (IU/L) | Creatinine | Albumin | Total cholesterol (units/mg) | Triglycerides (units/mg) |
|---|---|---|---|---|---|---|---|
| Normal control | 92.26 ± 0.57 | 234.34 ± 1.15 | 144.18 ± 0.57 | 1.52 ± 0.11 | 2.11 ± 0.17 | 141.40 ± 1.15 | 41.88 ± 0.28 |
| Diabetic control | 207.21 ± 1.15c | 496.97 ± 2.30c | 296.80 ± 2.30c | 7.55 ± 0.28c | 5.9 ± 0.28c | 213.97 ± 1.73c | 91.81 ± 0.57c |
| TOL | 154.85 ± 0.57c,d | 298.05 ± 2.30c,d | 238.58 ± 1.45c,d | 3.78 ± 0.057c,d | 3.51 ± 0.115b,d | 167.03 ± 0.57c,d | 52.85 ± 0.28c,d |
| PJ | 184.58 ± 1.73c,d | 346.13 ± 2.8c,d | 255.89 ± 1.73c,d | 3.75 ± 0.17c,d | 3.92 ± 0.14c,d | 181.68 ± 1.15c,d | 81.47 ± 0.57c,d |
| TOL + PJ | 124.75 ± 0.57c,d,f | 251.23 ± 1.15c,d,f | 191.69 ± 4.37c,d,f | 2.34 ± 0.11a,d,f | 2.57 ± 0.11d,e | 149.76 ± 1.15b,d,f | 48.34 ± 0.28c,d,f |
All values are mean ± SEM, n = 8.
ap < 0.05, bp < 0.01, and cp < 0.001, when compared to normal control; dp < 0.001 compared to diabetic control; ep < 0.05, and fp < 0.001 when compared to the group treated with TOL alone.
ALP, alkaline phosphate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PJ, pomegranate juice; SEM, standard error of the mean; TOL, tolbutamide.